Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

NCT05789524 is registered in ClinicalTrials.gov with ApcinteX Ltd as lead sponsor.

NCT NCT05789524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
Lead sponsor
ApcinteX Ltd
Phase
Phase 2
Overall status
Terminated
Start date
July 6, 2023
Completion date
February 28, 2025
Enrollment
60 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, hemophilia b